2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

• Main Authors: Ruperto N (Author), Quartier P (Author), Wulffraat N (Author), Woo P (Author), Loy A (Author), Mouy R (Author), Bader-Meunier B (Author), Prakken B (Author), Noseda E (Author), Rordorf C (Author)
• Format: Book
• Published: BMC, 2008-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Item Description

10.1186/1546-0096-6-S1-S2
1546-0096